Standout Papers

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open... 2018 2026 2020 2023 246
  1. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial (2018)
    Giuseppe Lombardi, Gian Luca De Salvo et al. The Lancet Oncology

Immediate Impact

60 standout
Sub-graph 1 of 23

Citing Papers

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies
2025 Standout
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
1 intermediate paper

Works of Simona Rizzato being referenced

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)
2021
Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis
2020
and 2 more

Author Peers

Author Last Decade Papers Cites
Simona Rizzato 143 288 135 24 428
Raquel Luque 116 197 100 34 471
Benedikte Hasselbalch 133 387 88 22 476
Jethro Hu 81 288 92 34 457
Sigmund Hsu 156 306 114 25 480
Sarah Gaffey 78 239 143 22 392
Richard Zuniga 207 355 88 15 489
Iyad Alnahhas 113 232 113 34 461
Joerg Felsberg 77 243 74 21 432
Jeffrey Raizer 153 214 127 12 374
Thuy Trinh 129 163 144 18 490

All Works

Loading papers...

Rankless by CCL
2026